Oncology and Hematology

Episodes 1-16 of 128

• 

  RestartResume

  Global Perspectives on Perioperative Immunotherapy in LA HNSCC

  RestartResume

  Global Perspectives on Perioperative Immunotherapy in LA HNSCC

  CME/CE

  Global Perspectives on Perioperative Immunotherapy in LA HNSCC

  0.25 credits

  • 

    

    Kevin J Harrington, PhD, FRCP, FRCR, FRSB

  • 

    

    Christophe Le Tourneau, MD, PhD

  0.25 credits

• 

  RestartResume

  Advanced Therapeutic Strategies and Resistance Mechanisms in CLL

  RestartResume

  Advanced Therapeutic Strategies and Resistance Mechanisms in CLL

  CME/CE

  Advanced Therapeutic Strategies and Resistance Mechanisms in CLL

  0.25 credits

  • 

    

    Shankara Paneesha, MD FRCP FRCPath

  0.25 credits

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  MinuteCE®

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  RestartResume

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  MinuteCE®

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  RestartResume

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  MinuteCE®

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  MinuteCE®

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  MinuteCE®

  Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer

  1.25 credits 9 episodes

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 credits 9 episodes

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  1.00 credit 10 episodes

  • 

    

    John M. Kirkwood, MD

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Applications of Emerging Data in Resectable NSCLC

  RestartResume

  Applications of Emerging Data in Resectable NSCLC

  MinuteCE®

  Applications of Emerging Data in Resectable NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  MinuteCE®

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  1.00 program credit

  • 

    

    Sapna Patel, MD

  • 

    

    John M. Kirkwood, MD

  1.00 program credit

• 

  RestartResume

  MET and Other Emerging Targets in Metastatic NSCLC

  RestartResume

  MET and Other Emerging Targets in Metastatic NSCLC

  MinuteCE®

  MET and Other Emerging Targets in Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC

  RestartResume

  Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC

  MinuteCE®

  Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  MinuteCE®

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  MinuteCE®

  HER2-Driven Strategies in Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• Prev
• 1
• 2
• 3
• …
• 7
• 8
• Next